Latest On Prevail Therapeutics Inc (PRVL):
About Prevail Therapeutics Inc (PRVL):
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
General
- Name Prevail Therapeutics Inc
- Symbol PRVL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 66
- Fiscal Year EndDecember
- IPO Date2019-06-20
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.prevailtherapeutics.com
Valuation
- Price/Book (Most Recent Quarter) 7
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.71
- Return on Assets -29%
- Return on Equity -52%
- Earnings Per Share -$7.80
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 787.7 million
- EBITDA -38527688
- Analyst Target Price $23.63
- Book Value Per Share $5.34
Share Statistics
- Shares Outstanding 34.25 million
- Shares Float 11.16 million
- % Held by Insiders 1300%
- % Held by Institutions 92.42%
- Shares Short 1.01 million
- Shares Short Prior Month 1.1 million
- Short Ratio 1.3
- Short % of Float 6%
- Short % of Shares Outstanding 3%
Technicals
- 52 Week High $23.35
- 52 Week Low $9.21
- 50 Day Moving Average 23.03
- 200 Day Moving Average 13.95
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Prevail Therapeutics Inc (PRVL) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Prevail Therapeutics Inc (PRVL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-09-30 | 2020-11-13 | $N/A | -$0.55 | -$0.65 | 14.83% |
2020-06-30 | 2020-08-11 | $N/A | -$0.66 | -$0.57 | -16.55% |
2020-03-31 | 2020-05-14 | $N/A | -$0.56 | -$0.48 | -15.51% |
2019-12-31 | 2020-03-26 | $N/A | -$0.54 | -$0.63 | 14.38% |
2019-09-30 | 2019-11-12 | $N/A | -$0.62 | -$0.48 | -28.28% |
2019-06-30 | 2019-08-14 | $N/A | -$0.58 | -$0.54 | -7.41% |
Prevail Therapeutics Inc (PRVL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Prevail Therapeutics Inc (PRVL) Chart:
Prevail Therapeutics Inc (PRVL) News:
Below you will find a list of latest news for Prevail Therapeutics Inc (PRVL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Prevail Therapeutics Inc (PRVL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Prevail Therapeutics Inc (PRVL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-07-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1714798/000119312520185248/0001193125-20-185248-index.htm |
2019-04-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1714798/000000000019007509/0000000000-19-007509-index.htm |
2019-05-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1714798/000000000019008851/0000000000-19-008851-index.htm |
2019-06-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1714798/000000000019009397/0000000000-19-009397-index.htm |
2020-07-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1714798/000000000020006043/0000000000-20-006043-index.htm |
2019-06-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1714798/000093583619000360/0000935836-19-000360-index.htm |
2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1714798/000093583620000149/0000935836-20-000149-index.htm |
2019-06-27 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1714798/000094787119000475/0000947871-19-000475-index.htm |
2019-03-27 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1714798/000095012319002856/0000950123-19-002856-index.htm |
2019-05-08 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1714798/000095012319004004/0000950123-19-004004-index.htm |
2019-05-07 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1714798/000095012319004005/0000950123-19-004005-index.htm |
2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1714798/000110465920021902/0001104659-20-021902-index.htm |
2020-10-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1714798/000110465920113414/0001104659-20-113414-index.htm |
2019-05-24 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1714798/000119312519157078/0001193125-19-157078-index.htm |
2019-05-24 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1714798/000119312519157094/0001193125-19-157094-index.htm |
2019-05-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1714798/000119312519159979/0001193125-19-159979-index.htm |
2019-06-10 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1714798/000119312519168749/0001193125-19-168749-index.htm |
2019-06-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1714798/000119312519168761/0001193125-19-168761-index.htm |
2019-06-13 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1714798/000119312519172517/0001193125-19-172517-index.htm |
2019-06-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1714798/000119312519174780/0001193125-19-174780-index.htm |
2019-06-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1714798/000119312519174791/0001193125-19-174791-index.htm |
2019-06-19 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1714798/000119312519176016/0001193125-19-176016-index.htm |
2019-06-20 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1714798/000119312519177602/0001193125-19-177602-index.htm |
2019-06-24 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1714798/000119312519180270/0001193125-19-180270-index.htm |
2019-06-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312519181337/0001193125-19-181337-index.htm |
2019-08-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312519222603/0001193125-19-222603-index.htm |
2019-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312519242120/0001193125-19-242120-index.htm |
2019-10-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312519264057/0001193125-19-264057-index.htm |
2019-11-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312519294797/0001193125-19-294797-index.htm |
2019-12-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312519323101/0001193125-19-323101-index.htm |
2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312520004748/0001193125-20-004748-index.htm |
2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312520006007/0001193125-20-006007-index.htm |
2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1714798/000119312520035624/0001193125-20-035624-index.htm |
2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1714798/000119312520035774/0001193125-20-035774-index.htm |
2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312520059726/0001193125-20-059726-index.htm |
2020-03-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1714798/000119312520087079/0001193125-20-087079-index.htm |
2020-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1714798/000119312520121009/0001193125-20-121009-index.htm |
2020-04-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1714798/000119312520121018/0001193125-20-121018-index.htm |
2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312520171460/0001193125-20-171460-index.htm |
2020-07-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1714798/000119312520185248/0001193125-20-185248-index.htm |
2020-07-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1714798/000119312520188026/0001193125-20-188026-index.htm |
2020-08-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1714798/000119312520215724/0001193125-20-215724-index.htm |
2020-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312520243118/0001193125-20-243118-index.htm |
2020-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000119312520283331/0001193125-20-283331-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038115/0001209191-19-038115-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038117/0001209191-19-038117-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038119/0001209191-19-038119-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038121/0001209191-19-038121-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038122/0001209191-19-038122-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038123/0001209191-19-038123-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038124/0001209191-19-038124-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038127/0001209191-19-038127-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038129/0001209191-19-038129-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038130/0001209191-19-038130-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038131/0001209191-19-038131-index.htm |
2019-06-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119038133/0001209191-19-038133-index.htm |
2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039015/0001209191-19-039015-index.htm |
2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039126/0001209191-19-039126-index.htm |
2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039127/0001209191-19-039127-index.htm |
2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039130/0001209191-19-039130-index.htm |
2019-11-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119056998/0001209191-19-056998-index.htm |
2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919119057001/0001209191-19-057001-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018117/0001209191-20-018117-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018118/0001209191-20-018118-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018121/0001209191-20-018121-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018123/0001209191-20-018123-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018129/0001209191-20-018129-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018133/0001209191-20-018133-index.htm |
2020-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018137/0001209191-20-018137-index.htm |
2020-06-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120034218/0001209191-20-034218-index.htm |
2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120034219/0001209191-20-034219-index.htm |
2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120038055/0001209191-20-038055-index.htm |
2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120038056/0001209191-20-038056-index.htm |
2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120038057/0001209191-20-038057-index.htm |
2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120038058/0001209191-20-038058-index.htm |
2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120038059/0001209191-20-038059-index.htm |
2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120038060/0001209191-20-038060-index.htm |
2020-09-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120050090/0001209191-20-050090-index.htm |
2020-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1714798/000120919120050091/0001209191-20-050091-index.htm |
2019-06-13 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1714798/000135445719000310/0001354457-19-000310-index.htm |
2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000156459019031956/0001564590-19-031956-index.htm |
2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1714798/000156459019031957/0001564590-19-031957-index.htm |
2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000156459019042617/0001564590-19-042617-index.htm |
2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1714798/000156459019042732/0001564590-19-042732-index.htm |
2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000156459020012979/0001564590-20-012979-index.htm |
2020-03-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1714798/000156459020012986/0001564590-20-012986-index.htm |
2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000156459020025266/0001564590-20-025266-index.htm |
2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1714798/000156459020025274/0001564590-20-025274-index.htm |
2020-08-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1714798/000156459020039112/0001564590-20-039112-index.htm |
2020-08-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1714798/000156459020039115/0001564590-20-039115-index.htm |
2018-03-14 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1714798/000171479818000002/0001714798-18-000002-index.htm |
2019-06-19 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1714798/999999999519001379/9999999995-19-001379-index.htm |
2020-07-08 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1714798/999999999520001719/9999999995-20-001719-index.htm |
2019-05-14 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1714798/999999999719004397/9999999997-19-004397-index.htm |
2019-06-18 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1714798/999999999719005627/9999999997-19-005627-index.htm |
Prevail Therapeutics Inc (PRVL) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Prevail Therapeutics Inc (PRVL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1300%Institutional Ownership: 9242%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2019-12-24 | Emily Minkow | Chief Business Officer | Buy | 13,000.00 | 0.18 | 2,340.00 | 13,000.00 | https://www.sec.gov/Archives/edgar/data/1714798/000120919120018117/0001209191-20-018117-index.htm |
2019-06-24 | CARL L GORDON | Director | Buy | 882,352.00 | 17.00 | 14,999,984.00 | 13,822,463.00 | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039127/0001209191-19-039127-index.htm |
2019-06-24 | ORBIMED ADVISORS LLC | Director | Buy | 882,352.00 | 17.00 | 14,999,984.00 | 13,822,463.00 | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039126/0001209191-19-039126-index.htm |
2019-06-24 | Peter A. Thompson | Director | Buy | 882,352.00 | 17.00 | 14,999,984.00 | 13,822,463.00 | https://www.sec.gov/Archives/edgar/data/1714798/000120919119039130/0001209191-19-039130-index.htm |